BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 19861628)

  • 41. Bacterial clearance with WHO--recommended multidrug regimen for multibacillary leprosy.
    Kishore BN; Shetty JN
    Indian J Lepr; 1995; 67(3):301-8. PubMed ID: 8576609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relapse of leprosy after multidrug therapy.
    Dasananjali K
    J Med Assoc Thai; 1996 Oct; 79(10):635-9. PubMed ID: 8996998
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relapse in MB leprosy patients treated with 24 months of MDT in south west China: a short report.
    Shen J; Liu M; Zhang J; Su W; Ding G
    Lepr Rev; 2006 Sep; 77(3):219-24. PubMed ID: 17172002
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study.
    Ebenezer GJ; Job A; Abraham S; Arunthathi S; Rao PS; Job CK
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):292-7. PubMed ID: 10575409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study of HLA-DR expression on skin lesions of leprosy before and during multiple drug therapy.
    Abdel Latif AM; Essa EA
    Int J Lepr Other Mycobact Dis; 2002 Jun; 70(2):104-10. PubMed ID: 12211894
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A study of relapse after MDT in a district in West Bengal, India.
    Haldar A; Mahapatra BS; Mundle M; Haldar S; Saha AK
    Indian J Lepr; 2003; 75(1):1-8. PubMed ID: 15253389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT.
    Shetty VP; Khambati FA; Ghate SD; Capadia GD; Pai VV; Ganapati R
    Lepr Rev; 2010 Mar; 81(1):41-58. PubMed ID: 20496569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy.
    Balagon MF; Cellona RV; Abalos RM; Gelber RH; Saunderson PR
    Lepr Rev; 2010 Mar; 81(1):27-33. PubMed ID: 20496567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts.
    Torres P; Camarena JJ; Gomez JR; Nogueira JM; Gimeno V; Navarro JC; Olmos A
    Lepr Rev; 2003 Mar; 74(1):18-30. PubMed ID: 12669929
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A follow-up study of multibacillary Hansen's disease patients treated with multidrug therapy (MDT) or MDT + immunotherapy (IMT).
    Rada E; Ulrich M; Aranzazu N; Rodriguez V; Centeno M; Gonzalez I; Santaella C; Rodriguez M; Convit J
    Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):320-7. PubMed ID: 9401484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction of lepromin positivity following immuno-chemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with the candidate antileprosy vaccine.
    Sharma P; Kar HK; Misra RS; Mukherjee A; Kaur H; Mukherjee R; Rani R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):259-69. PubMed ID: 10575405
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.
    Rao PN; Suneetha S; Pratap DV
    Lepr Rev; 2011 Sep; 82(3):244-52. PubMed ID: 22125932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospective study, comparing the experience of multibacillary patients receiving either 12 or 24 months WHO-MDT.
    Balagon M; Saunderson PR; Gelber RH
    Lepr Rev; 2011 Sep; 82(3):213-21. PubMed ID: 22125929
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Multi-drug therapy trials for leprosy in Senegal: first observations relative to liver tolerance of multibacillary patients. Therapeutic consequences].
    Millan J; Roux G; Loko S; Naudin JC; Boucher P; Bodian M; Camara M; Moreira-Diop T; Grosset J
    Acta Leprol; 1986; 4(4):427-44. PubMed ID: 3296613
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy.
    Pattyn S; Grillone S
    Lepr Rev; 2002 Sep; 73(3):245-7. PubMed ID: 12449889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Longitudinal ocular survey of 202 Filipino patients with multi-bacillary (MB) leprosy treated with 2 year WHO-multiple drug therapy.
    Ravanes JM; Cellona RV; Balagon M; Abalos RM; Walsh GP; Walsh DS
    Southeast Asian J Trop Med Public Health; 2011 Mar; 42(2):323-30. PubMed ID: 21710853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of viable organisms in leprosy patients treated with multidrug therapy.
    Gupta UD; Katoch K; Singh HB; Natrajan M; Sharma VD; Katoch VM
    Acta Leprol; 1999; 11(3):89-92. PubMed ID: 10544720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary dapsone resistance in Cebu, The Philippines; cause for concern.
    dela Cruz E; Cellona RV; Balagon MV; Villahermosa LG; Fajardo TT; Abalos RM; Tan EV; Walsh GP
    Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):253-6. PubMed ID: 8862258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug resistance patterns in Mycobacterium leprae isolates from relapsed leprosy patients attending The Leprosy Mission (TLM) Hospitals in India.
    Lavania M; Jadhav RS; Chaitanya VS; Turankar R; Selvasekhar A; Das L; Darlong F; Hambroom UK; Kumar S; Sengupta U
    Lepr Rev; 2014 Sep; 85(3):177-85. PubMed ID: 25509718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.